URGN as reported
UroGen Pharma Ltd. reported $140M of revenue over the trailing twelve months, +53% on the year before. 10 reported series are charted on this page, each one as filed.
$140M
Revenue, trailing twelve months · to Q1 2026 · +53% against the twelve months before
- Net Income
- −$133M
Net Income · −3.8% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$166M
Free Cash Flow · +55% year on year · trailing twelve months to Q1 2026
- Op Margin
- −90%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $140M | +53% | Q1 2026 |
| Net Income | −$133M | −3.8% | Q1 2026 |
| EPS | −$4.96 | n/a | Q4 2021 · 17 quarters behind |
| Gross Margin | 89% | n/a | Q1 2026 |
| Op Margin | −90% | n/a | Q1 2026 |
| Net Margin | −111% | n/a | Q1 2026 |
| ROE | 140% | n/a | Q1 2026 |
| ROA | −73% | n/a | Q1 2026 |
| ROIC | 77% | n/a | Q1 2026 |
| Free Cash Flow | −$166M | +55% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
UroGen Pharma Ltd. (URGN) - Revenue & ProfitRevenue & ProfitUroGen Pharma Ltd. (URGN)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com